- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Scientists Provide Technical Due Diligence To Investor Funds
August 30, 2005
A new venture, Bio Life Technical, including leading researchers within Nanotechnology and Personalized Healthcare, such as Professor Chris Toumazou and Professor Sir Magdi Yacoub of Imperial College, London, is being launched in London, UK, providing independent due diligence services to investors, globally. Bio Life Technical is structured to aid venture capital groups, investment banks, business angels and institutional investors by providing a single contact point and managing the technical due diligence reporting process on behalf of prospective investor clients. This will save time, resources and, therefore, money for the investment community. Professor Chris Toumazou said, “Medical Device technology is truly interdisciplinary. Bio Life Technical’s strategy of providing technical due diligence by expert professors from core disciplines and world class experts working with interdisciplinary institutes, such as Imperial College’s Institute of Biomedical Engineering, will enable a more thorough scientific evaluation of the technology.”
In addition, Bio Life Technical can estimate a quantitative commercial value for a device, even though it is at a pre-development stage without the usual financial inputs to rely on. Aiden Williamson, a partner in Bio Life Technical said “The Bio Life Technical service is a welcome development in the field of technical due diligence that will give investors a clear edge when it comes to the evaluation of investment opportunities.”
By specializing in Nanotechnology and Personalized Healthcare, Bio Life Technical is concentrating upon areas of high contemporary and future importance to the investment and financial community, industry, plus scientific and healthcare organisations. Each of the technologies could cause revolutionary and, in some cases, disruptive change in the status quo and growth prospects of most technology dependent business sectors. For this reason, Bio Life Technical retains a cross-disciplinary approach, ensuring a truly comprehensive reporting structure. The value-added element of the Bio Life Technical offering is technical analysis that cannot normally be undertaken by venture capital firms, early stage investors.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
Harris & Harris Group Sponsors NYC American Heart Association's Health Sciences Innovation Investment Forum: Co-founder of Harris & Harris Group Portfolio Company TARA Biosystems to Speak About the Value of Tissue Engineering Technology April 21st, 2015
Long Island Capital Alliance Announces Participants for Brookhaven National Laboratory Technology Transfer Capital Forum on May 8: Keynote Speaker Dr. Doon Gibbs, Director of Brookhaven National Laboratory April 16th, 2015
Graphenea embarks on a new era April 16th, 2015